Chronic kidney disease, Hypertension CKD, Hypertension, Proteinurira, Esaxerenone, ARB
Conditions
Interventions
Esaxerenone add-on to ARB
Esaxerenone, ARB
Sponsors
Masaki Takao
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients whose written consent has been obtained from the patient 2. Patients of any gender, aged between 18 and 85 years at the time of consent 3. Patients with poorly controlled hypertension (systolic blood pressure greater than 130 mmHg and/or diastolic blood pressure greater than 80 mmHg at examination within 4 weeks prior to enrollment) 4. Patients with eGFR (mL/min/1.73m2) >30 and 0.15 g/gCr) prior to enrollment 5. Patients who have been taking a dose of antihypertensive medication (ARB: losartan 25-50 mg, irbesartan 50-100 mg, telmisartan 40 mg, olmesartan 10-20 mg, or azilsartan 20 mg) continuously for at least 4 weeks without change 6.Ppatients who are able to continuously measure blood pressure with a home blood pressure monitor
Exclusion criteria
Exclusion criteria: 1. Patients with eGFR (mL/min/1.73m2) 3.5 g/gCr prior to enrollment 3. Patients with hypersensitivity to esaxerenone 4. Patients with hyperkalemia or serum potassium level > 5.0 mEq/L at the start of treatment with this drug 5. Patients receiving potassium retaining diuretics (spironolactone, triamterene, potassium canrenoate), aldosterone antagonists (eplerenone) or potassium preparations (potassium chloride, potassium gluconate, potassium aspartate, potassium iodide, potassium acetate) 6. Pregnant, lactating, possibly pregnant or planning to become pregnant 7. Patients undergoing anticancer therapy 8. Patients who are unable to comply with their medication regimen 9. Other patients who are judged by the principal investigator or subinvestigator to be inappropriate as subjects for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent reduction in UPCR at 12 weeks post treatment compared to enrollment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in eGFR, Change in systolic and diastolic blood pressure, Percentage of patients with improved UPCR rank at 12 weeks post treatment compared to enrollment, Percentage of patients with improved UPCR at 12 weeks post treatment compared to enrollment, Change in NT-proBNP, serum K levels, safety assessment | — |
Contacts
Public ContactAkira Takahashi
Hiroshima University Hospital
Outcome results
None listed